Amgen and Boehringer Ingelheim have signed an agreement under which Boehringer will acquire the rights to, and the assets of, Amgen’s Fremont CA development and manufacturing facility. The 100,000-sq.-ft. manufacturing facility currently has approximately 360 employees and includes a pilot plant and process development labs. The transaction is expected to close in March. “With great enthusiasm, we look forward to welcoming the Amgen Fremont employees into the Boehringer Ingelheim family...